24/7 Market News Snapshot 25 July, 2025 – Phio Pharmaceuticals Corp. Common Stock (NASDAQ:PHIO)
DENVER, Colo., 25 July, 2025 (www.247marketnews.com) – (NASDAQ:PHIO) are discussed in this article.
Phio Pharmaceuticals Corp. is experiencing substantial momentum in the pre-market as trading reaches $3.423, reflecting an impressive increase of 36.37% from the previous day’s close of $2.510. This surge is accompanied by a robust trading volume of 5.06 million shares, highlighting significant interest from investors and confidence in the company’s growth trajectory. Analysts are watching closely, as such pronounced price movements often signal the potential for a market breakout, suggesting that Phio is poised for further advancements.
In addition to the stock rally, Phio Pharmaceuticals has positioned itself strategically within the oncology landscape through a recent agreement with a prominent U.S. manufacturer for drug substance development services. This partnership is set to enhance the development of Phio’s lead clinical candidate, PH-762, leveraging the company’s innovative INTASYL® gene silencing technology. The collaboration will facilitate critical analytical and process development, as well as commercial-grade production of PH-762.
This announcement is particularly timely, as Phio is in the process of enrolling participants for the fifth and final cohort of its Phase 1b dose escalation study, targeting various types of skin cancers, including cutaneous squamous cell carcinoma, Merkel cell carcinoma, and melanoma.
Mr. Bitterman, President and CEO of Phio Pharmaceuticals, emphasized the strategic advantages of working with a reputable U.S.-based organization known for its expertise in oligonucleotide chemistry. PH-762 is designed to target the PD-1 gene, presenting a novel treatment pathway for patients in need of non-surgical options.
As Phio Pharmaceuticals embarks on its clinical journey, stakeholders can anticipate pivotal developments that may enhance therapeutic modalities in the fight against cancer, reinforcing the company’s commitment to patients and innovation in the sector.